Milan Scheidegger is a visionary and integrative thinker with an academic background in medicine, neuroscience, philosophy, and psychiatry. He is driven by the passion to understand the nature of consciousness from its molecular basis up to the level of phenomenal experience.

After his MD-PhD training in functional and molecular brain imaging at the Institute for Biomedical Engineering (ETH Zurich) he continues to research the neurobiology and pharmacology of altered states of consciousness.

As a junior group leader of Psychedelic Research & Therapy Development at the Department of Psychiatry, Psychotherapy, and Psychosomatics (University of Zurich), he aims at developing novel approaches to combine pharmacotherapy and psychotherapy. Specifically, he investigates the therapeutic potential of psychedelics such as ketamine, psilocybin, ayahuasca and DMT to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.

He co-founded Reconnect Foundation, a non-profit organization based in Switzerland, with the mission to develop transformative treatments for mental health care. As a psychotherapist he is trained in interpersonal and cognitive behavioral therapy, ego-state therapy, acceptance and commitment therapy, mindfulness-based and psychedelic-assisted therapy.

Beyond empirical research, he earned an M.A. degree in History and Philosophy of Knowledge (ETH Zurich). As part of his studies in biosemiotics, philosophy of mind, epistemology and phenomenology of consciousness, mindfulness and deep ecology, he developed a broader perspective on life. On his ethnobotanical expeditions to Mexico, Colombia and Brazil, he explored the traditional use of psychoactive plants in indigenous rituals.

He is member of the Swiss Society for Psycholytic Therapy (SÄPT) and the MIND European Foundation for Psychedelic Science. He is former scholar of the Swiss Study Foundation and received the Inger Salling Award for Psychiatry (2019) and the Young Investigators Award from the Swiss Society of Biological Psychiatry (2013).